<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">33123992</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0065-2598</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>1270</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Advances in experimental medicine and biology</Title>
          <ISOAbbreviation>Adv Exp Med Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Eph/Ephrin Signaling in the Tumor Microenvironment.</ArticleTitle>
        <Pagination>
          <StartPage>45</StartPage>
          <EndPage>56</EndPage>
          <MedlinePgn>45-56</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-030-47189-7_3</ELocationID>
        <Abstract>
          <AbstractText>The Eph/ephrin system plays a vital role in diverse physiological events such as neurogenesis, vasculogenesis, and cell adhesion. Expression analysis of mRNA and protein in clinical samples revealed the involvement of the Eph/ephrin system in tumorigenesis, Alzheimer's disease, and atherosclerosis. Therefore, the Eph/ephrin system is considered a promising therapeutic target. However, no molecularly targeted drug against Ephs and ephrins is being used in the clinic thus far.Tumors are composed of various types of cells, including fibroblasts, immune cells, and endothelial cells. Recent studies showed the contribution of these cells to tumor growth, tumor progression, drug resistance, and metastasis. In this chapter, we discuss the role of Eph/ephrin system in the tumor microenvironment and describe its functions in tumor initiation, angiogenesis, cancer stem cell, tumor immunity, and also the metastatic environment.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ieguchi</LastName>
            <ForeName>Katsuaki</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Tokyo Women's Medical University, Tokyo, Japan. kieguchi@twmu.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maru</LastName>
            <ForeName>Yoshiro</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Tokyo Women's Medical University, Tokyo, Japan. maru.yoshiro@twmu.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Adv Exp Med Biol</MedlineTA>
        <NlmUniqueID>0121103</NlmUniqueID>
        <ISSNLinking>0065-2598</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D036342">Ephrins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D036081">Receptors, Eph Family</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D036342" MajorTopicYN="N">Ephrins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D036081" MajorTopicYN="N">Receptors, Eph Family</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="Y">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ADAM</Keyword>
        <Keyword MajorTopicYN="N">Angiogenesis</Keyword>
        <Keyword MajorTopicYN="N">Breast cancer</Keyword>
        <Keyword MajorTopicYN="N">Cancer stem cell</Keyword>
        <Keyword MajorTopicYN="N">Colon cancer</Keyword>
        <Keyword MajorTopicYN="N">Eph</Keyword>
        <Keyword MajorTopicYN="N">Ephrin</Keyword>
        <Keyword MajorTopicYN="N">Immune therapy</Keyword>
        <Keyword MajorTopicYN="N">MAPK</Keyword>
        <Keyword MajorTopicYN="N">Metastasis</Keyword>
        <Keyword MajorTopicYN="N">PD-L1</Keyword>
        <Keyword MajorTopicYN="N">Prognosis</Keyword>
        <Keyword MajorTopicYN="N">Ras</Keyword>
        <Keyword MajorTopicYN="N">RhoA</Keyword>
        <Keyword MajorTopicYN="N">Tumor Progression</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>30</Day>
          <Hour>5</Hour>
          <Minute>59</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33123992</ArticleId>
        <ArticleId IdType="doi">10.1007/978-3-030-47189-7_3</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">33123992</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0065-2598</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>1270</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Advances in experimental medicine and biology</Title>
          <ISOAbbreviation>Adv Exp Med Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Eph/Ephrin Signaling in the Tumor Microenvironment.</ArticleTitle>
        <Pagination>
          <StartPage>45</StartPage>
          <EndPage>56</EndPage>
          <MedlinePgn>45-56</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-030-47189-7_3</ELocationID>
        <Abstract>
          <AbstractText>The Eph/ephrin system plays a vital role in diverse physiological events such as neurogenesis, vasculogenesis, and cell adhesion. Expression analysis of mRNA and protein in clinical samples revealed the involvement of the Eph/ephrin system in tumorigenesis, Alzheimer's disease, and atherosclerosis. Therefore, the Eph/ephrin system is considered a promising therapeutic target. However, no molecularly targeted drug against Ephs and ephrins is being used in the clinic thus far.Tumors are composed of various types of cells, including fibroblasts, immune cells, and endothelial cells. Recent studies showed the contribution of these cells to tumor growth, tumor progression, drug resistance, and metastasis. In this chapter, we discuss the role of Eph/ephrin system in the tumor microenvironment and describe its functions in tumor initiation, angiogenesis, cancer stem cell, tumor immunity, and also the metastatic environment.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ieguchi</LastName>
            <ForeName>Katsuaki</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Tokyo Women's Medical University, Tokyo, Japan. kieguchi@twmu.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maru</LastName>
            <ForeName>Yoshiro</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Tokyo Women's Medical University, Tokyo, Japan. maru.yoshiro@twmu.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Adv Exp Med Biol</MedlineTA>
        <NlmUniqueID>0121103</NlmUniqueID>
        <ISSNLinking>0065-2598</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D036342">Ephrins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D036081">Receptors, Eph Family</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D036342" MajorTopicYN="N">Ephrins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D036081" MajorTopicYN="N">Receptors, Eph Family</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="Y">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ADAM</Keyword>
        <Keyword MajorTopicYN="N">Angiogenesis</Keyword>
        <Keyword MajorTopicYN="N">Breast cancer</Keyword>
        <Keyword MajorTopicYN="N">Cancer stem cell</Keyword>
        <Keyword MajorTopicYN="N">Colon cancer</Keyword>
        <Keyword MajorTopicYN="N">Eph</Keyword>
        <Keyword MajorTopicYN="N">Ephrin</Keyword>
        <Keyword MajorTopicYN="N">Immune therapy</Keyword>
        <Keyword MajorTopicYN="N">MAPK</Keyword>
        <Keyword MajorTopicYN="N">Metastasis</Keyword>
        <Keyword MajorTopicYN="N">PD-L1</Keyword>
        <Keyword MajorTopicYN="N">Prognosis</Keyword>
        <Keyword MajorTopicYN="N">Ras</Keyword>
        <Keyword MajorTopicYN="N">RhoA</Keyword>
        <Keyword MajorTopicYN="N">Tumor Progression</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>30</Day>
          <Hour>5</Hour>
          <Minute>59</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33123992</ArticleId>
        <ArticleId IdType="doi">10.1007/978-3-030-47189-7_3</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
